核型
染色体异常
染色体
异常
骨髓增生异常综合症
内科学
细胞遗传学
国际预后积分系统
医学
7号染色体(人类)
生物
病理
遗传学
骨髓
基因
精神科
作者
Jin Qian,Jun Xia,Xin Xie,Jing Wang,Jingjue Mao,Xin Zhou
出处
期刊:PubMed
[National Institutes of Health]
日期:2021-10-01
卷期号:29 (5): 1528-1532
被引量:1
标识
DOI:10.19746/j.cnki.issn.1009-2137.2021.05.024
摘要
OBJECTIVE: To investigate the clinical characteristics of myelodysplastic syndrome (MDS) patients with chromosome 21 karyotype abnormality. METHODS: The clinical data of 155 patients with MDS were retrospectively analyzed, the clinical characteristics, survival and factors affecting prognosis of chromosome 21 karyotype abnormality patients were analyzed. RESULTS: Among 155 MDS patients, 4 were 5q- syndrome, 41 were MDS-EB-I, 35 were MDS-EB-II, 27 were MDS-SLD, 46 were MDS-MLD, 1 was MDS-RS-SLD, and 1 was MDS-U. The median follow-up time was 11.0(0.1-120.9) months. Among 155 MDS patients, 13 (9.0%) showed chromosome 21 abnormalities. Among the 13 patients with chromosome 21 karyotype abnormalities, there were 5 cases with simple +21 karyotype, 1 case with del (21q12), 1 case with +8, +21, 1 case with i(21q), 1 case with 20q-, +21, and 4 cases with complex karyotype involving chromosome 21; including 2 cases of MDS-SLD, 4 cases of MDS-MLD, 5 cases of MDS-EB-I and 2 cases of MDS-EB-II. The median survival time of the patients was 3.1 (0.1-6.7) months. CONCLUSION: Chromosome 21 karyotype abnormality is rare in MDS, and the prognosis is worse than the patients without chromosome 21 abnormalities.
科研通智能强力驱动
Strongly Powered by AbleSci AI